SCHEMBL3019701

SCHEMBL3019701

COc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(Br)cc4Cl)CC3)n2)cc1OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.37
DRD4 P21917 5/20 0.37
DRD3 P35462 5/20 0.37
MAPT P10636 2/20 0.36
LMNA P02545 2/20 0.36
ALDH1A1 P00352 1/20 0.36
PPARG P37231 1/20 0.36
GFER P55789 1/20 0.36
NCOA2 Q15596 1/20 0.36
NCOA1 Q15788 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
UTS2R Q9UKP6 2/20 0.35
ERBB2 P04626 4/20 0.35
EPHA2 P29317 4/20 0.35
KDR P35968 3/20 0.35
EPHB4 P54760 3/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017066 0.92 DRD2 (0.35) DRD2DRD4DRD3MAPTLMNA
SCHEMBL3010744 0.92 HTR7 (0.38) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL3013312 0.92 GAA (0.39) DRD2DRD4DRD3MAPTLMNA
SCHEMBL3008114 0.90 CTSS (0.42) MAPTLMNAALDH1A1NPC1RAB9A
SCHEMBL2999691 0.90 RAB9A (0.37) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL3012728 0.89 HTR7 (0.41) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL3019234 0.89 ERBB2 (0.40) DRD2DRD4DRD3MAPTLMNA
SCHEMBL3001246 0.88 CTSS (0.35) DRD2DRD4DRD3MAPTLMNA
SCHEMBL3012960 0.88 LMNA (0.36) MAPTLMNAERBB2EPHA2KDR
SCHEMBL3004553 0.88 MAPT (0.40) DRD2DRD4DRD3MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA DRD2 573/4885DRD4 1124/4885DRD3 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.